Making sure that the renaissance of neuroscience drugs development is valued by HTA bodies and payers so patients and society benefit from therapeutic innovations
Dr. Keja joined IQVIA 16 years ago and now is Global Category Leader HEOR, HTA and Secondary Data, Real World-Evidence Solutions at IQVIA, drawing on deep expertise in market access, drug safety, health economics, secondary and primary data collection. His background includes four years as European head of pricing, reimbursement, health outcomes and market access consulting services at Quintiles and more than 13 years experience in the pharmaceutical industry, including senior-level international and global roles in sales management, strategic marketing, pricing and reimbursement and health economics. Dr Keja holds a PhD in Biophysics (Neurophysiology) from Vrije Universiteit in Amsterdam, a Masters in Medical Biology, and an undergraduate degree in Biology, both from Utrecht University. He was also visiting Professor in marketing management and access at the Institute of Health Policy & Management at Erasmus University for 10 years up to 2018.
The global burden of illness caused by mental health and neurological disorders is significant and continues to grow.
The WHO estimated the 2019 impact of mental health and neurological conditions with 256 million DALYs to exceed the 242 million DALYs globally for all malignant neoplasms.
Fortunately we are seeing encouraging R&D progress, with many new therapeutic options in late stage development. At the same moment, we have also seen high-profile setbacks in recent history. Developing innovative treatments for central nervous system (CNS) disorders still proves to be complex and time consuming. * Medical scientific research cannot be seen and performed in isolation. We see challenges due to a combination of scientific, practical and financial barriers.
This session will focus on how to overcome some of those practical and financial hurdles: recruitment of the right patients in studies, helping health care systems improve (early) diagnosis how to reward innovation and provide access to new therapeutic options.
On the latter we will dive deeper on aspects, important in the process of Health Technology Assessment.
This area is more relevant than ever with the upcoming European Joint Clinical Assessment.
We will analyze the impact of COA on CNS therapy HTAs and how different HTA bodies are dealing with minimal clinically important difference (MCID) on scale-based outcomes. Through this we close the loop back to R&D.